0001209191-18-039316.txt : 20180622
0001209191-18-039316.hdr.sgml : 20180622
20180622191116
ACCESSION NUMBER: 0001209191-18-039316
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180620
FILED AS OF DATE: 20180622
DATE AS OF CHANGE: 20180622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nagler David
CENTRAL INDEX KEY: 0001416175
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37833
FILM NUMBER: 18915641
MAIL ADDRESS:
STREET 1: ARYX THERAPEUTICS,INC.
STREET 2: 6300 DUMBARTON CIRCLE
CITY: FREMONT
STATE: CA
ZIP: 94555
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Audentes Therapeutics, Inc.
CENTRAL INDEX KEY: 0001628738
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461606174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
BUSINESS PHONE: 415-638-6556
MAIL ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-20
0
0001628738
Audentes Therapeutics, Inc.
BOLD
0001416175
Nagler David
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR
SAN FRANCISCO
CA
94108
0
1
0
0
SVP, HR & Corp. Affairs
Common Stock
2018-06-20
4
M
0
4700
2.1852
A
4700
D
Common Stock
2018-06-20
4
S
0
4700
45.2457
D
0
D
Common Stock
2018-06-20
4
M
0
300
2.1852
A
300
D
Common Stock
2018-06-20
4
S
0
300
46.0201
D
0
D
Stock Option (right to buy)
2.1852
2018-06-20
4
M
0
5000
0.00
D
2025-02-04
Common Stock
5000
32347
D
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. The lowest price at which shares were sold was $45.00 and the highest price at which shares were sold was $45.97. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
Represents the weighted average sale price. The lowest price at which shares were sold was $46.00 and the highest price at which shares were sold was $46.06.
The option vested as to 25% of the total shares on February 1, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 1, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.
/s/ Thomas Soloway as attorney-in-fact for David Nagler
2018-06-22